ADVANCED SOLID TUMORS
Clinical trials for ADVANCED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced cancer: ALK-N001 trial launches
Disease control Not yet recruitingThis study tests a new injectable drug, ALK-N001, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 190 adults will take part in this early-phase trial to check sa…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New hope for advanced cancer: SKB565 trial launches
Disease control Not yet recruitingThis study tests a new drug called SKB565 in 180 adults with advanced solid tumors who have no other treatment options. The goal is to see if the drug is safe and can shrink tumors. The study has three stages: finding the right dose, expanding the dose, and testing in specific tu…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:49 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests two experimental drugs, IMM2510 and IMM01, given together to adults with advanced solid tumors that have not responded to at least one prior treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth. About 104 pa…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
New immune cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage study is testing a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The main goals are to see if th…
Matched conditions: ADVANCED SOLID TUMORS
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 16, 2026 23:46 UTC
-
New hope for Hard-to-Treat cancers: drug targets RAS mutations
Disease control Not yet recruitingThis study tests a new drug called BPI-572270 in 120 adults with advanced solid tumors (lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The goal is to see if the drug is safe and can shrink or control the tumors. Participants must have already tried stan…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:43 UTC
-
New gene therapy targets advanced solid tumors in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a virus to deliver special immune cells (T cells) that are designed to recognize and attack cancer cell…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New cell therapy hopes to fight advanced tumors
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called GK01 in 10 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and how the body handles the therapy, while also looking at whether it can shrink tumors or control…
Matched conditions: ADVANCED SOLID TUMORS
Phase: EARLY_PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare cancers: precision trial launches in china
Disease control Not yet recruitingThis study tests new anti-cancer drugs and technologies in 600 people with rare advanced solid tumors that have stopped responding to standard treatments. Participants receive therapies matched to their tumor's unique genetic profile. The goal is to see if these treatments are sa…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New gene therapy targets advanced tumors in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. About 30 adults aged 18 to 70 will receive a single infusion and…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for advanced cancer patients: experimental drug XNW34017 enters human trials
Disease control Not yet recruitingThis study tests a new drug called XNW34017 in 150 people with advanced solid tumors who have run out of standard options. The goal is to see if the drug is safe and can shrink tumors. The trial has two phases: first finding the right dose, then testing that dose in more patients…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New drug aims to shrink hard-to-treat tumors in early human tests
Disease control Not yet recruitingThis study tests an experimental drug, SKB103, in 277 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right dose…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Lifeline for cancer patients: rollover study extends access to promising drug
Disease control Not yet recruitingThis study offers continued treatment with the drug RVU120 to people with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from it in an earlier study. Participants must have received at least 5 cycles of RVU120 and h…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New cell therapy GK01 targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called GK01 in 15 adults with advanced solid tumors (like stomach or lung cancer) that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also meas…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New drug targets stubborn cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called LCB02A in people with advanced solid tumors that have a specific marker (CLDN18.2) and have stopped responding to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, f…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New drug combo targets advanced cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, ovarian, or endometrial cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants will receive …
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Experimental combo aims to boost immune attack on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—in about 60 people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and see if the combina…
Matched conditions: ADVANCED SOLID TUMORS
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
Can your own immune cells fight advanced cancer? new study aims to find out
Disease control Not yet recruitingThis early-phase study is testing a new treatment for people with advanced lung, liver, colorectal, or breast cancer. The therapy uses a patient's own immune cells, which are collected, trained in a lab to better recognize and attack cancer, and then infused back into the body. T…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. • Aim: Disease control
Last updated May 05, 2026 11:57 UTC
-
New pill targets Hard-to-Treat cancers with KRAS mutations
Disease control Not yet recruitingThis early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New targeted cancer therapy begins first human testing
Disease control Not yet recruitingThis is the first human study of an experimental cancer drug called M7437, which targets a specific protein found on certain tumor cells. The study will test the safety, side effects, and early effectiveness of M7437 in 138 people with advanced solid tumors that have stopped resp…
Matched conditions: ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jan 26, 2026 13:59 UTC